Literature DB >> 16816519

Vincristine induced cranial polyneuropathy.

Ali Bay1, Cahide Yilmaz, Nebi Yilmaz, Ahmet Faik Oner.   

Abstract

We describe a 5-year-old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment. A 5-year-old girl was diagnosed preB cell Acute Lymphoblastic Leukemia (ALL). She received chemotherapy according to the previously described modified St. Jude total therapy studies XIII. Five days after the fourth dose of vincristine, she presented with bilateral ptosis. Neurological examination revealed bilateral ptosis, and complete external opthalmoplegia with normal pupillary and corneal reflexes. She received 3.8 mg cumulative dose of vincristin before development of ptosis. A neuroprotective and neuroregenerative treatment attempt with pyridoxine and pyridostigmine was initiated. The bilateral ptosis markedly improved after 7 days of pyridoxine and pyridostigmine treatment and completely resolved after two weeks. The both agents were given for 3 weeks and were well tolerated without any side effects. During the follow up period we did not observe residue or recurrence of the ptosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16816519     DOI: 10.1007/bf02759902

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  10 in total

Review 1.  Chemotherapy-induced peripheral neuropathy.

Authors:  Stefan Quasthoff; Hans Peter Hartung
Journal:  J Neurol       Date:  2002-01       Impact factor: 4.849

2.  Treatment of vincristine-induced bilateral ptosis with pyridoxine and pyridostigmine.

Authors:  Lars Müller; Christof M Kramm; Tobias Tenenbaum; Rüdiger Wessalowski; Ulrich Göbel
Journal:  Pediatr Blood Cancer       Date:  2004-03       Impact factor: 3.167

Review 3.  Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports.

Authors:  J D Chan
Journal:  Pharmacotherapy       Date:  1998 Nov-Dec       Impact factor: 4.705

Review 4.  Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study.

Authors:  Allen R Chauvenet; Vandana Shashi; Clifford Selsky; Elaine Morgan; Joanne Kurtzberg; Beverly Bell
Journal:  J Pediatr Hematol Oncol       Date:  2003-04       Impact factor: 1.289

Review 5.  Vincristine neurotoxicity. Pathophysiology and management.

Authors:  S S Legha
Journal:  Med Toxicol       Date:  1986 Nov-Dec

6.  Fulminant peripheral neuropathy with severe quadriparesis associated with vincristine therapy.

Authors:  S S Moudgil; J E Riggs
Journal:  Ann Pharmacother       Date:  2000-10       Impact factor: 3.154

7.  Benefit of high-dose methylprednisolone in comparison with conventional-dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-term follow-up.

Authors:  S Yetgin; M A Tuncer; M Cetin; F Gümrük; I Yenicesu; B Tunç; A F Oner; H Toksoy; A Koç; D Aslan; E Ozyürek; L Olcay; L Atahan; E Tunçbilek; A Gürgey
Journal:  Leukemia       Date:  2003-02       Impact factor: 11.528

8.  Clinical trial of pyridoxine to reduce vincristine neurotoxicity.

Authors:  D V Jackson; E K Pope; R A McMahan; M R Cooper; J N Atkins; R D Callahan; E H Paschold; R A Grimm; J O Hopkins; H B Muss
Journal:  J Neurooncol       Date:  1986       Impact factor: 4.130

9.  Colonic dysfunction in diabetes mellitus.

Authors:  W M Battle; W J Snape; A Alavi; S Cohen; S Braunstein
Journal:  Gastroenterology       Date:  1980-12       Impact factor: 22.682

10.  Vincristine treatment triggering the expression of asymptomatic Charcot-Marie-Tooth disease.

Authors:  Y Neumann; A Toren; G Rechavi; B Seifried; N G Shoham; M Mandel; G Kenet; N Sharon; M Sadeh; R Navon
Journal:  Med Pediatr Oncol       Date:  1996-04
  10 in total
  7 in total

1.  Use of pyridoxine and pyridostigmine in children with vincristine-induced neuropathy.

Authors:  Sinan Akbayram; Cihangir Akgun; Murat Doğan; Refah Sayin; Huseyin Caksen; Ahmet Faik Oner
Journal:  Indian J Pediatr       Date:  2010-06-08       Impact factor: 1.967

2.  Unilateral phrenic nerve palsy: a rare manifestation of vincristine neurotoxicity.

Authors:  Dhulika Dhingra; Gulshan Rai Sethi; Mukta Mantan
Journal:  Indian J Pediatr       Date:  2013-06-26       Impact factor: 1.967

3.  Chemotherapy-Induced Peripheral Neuropathy in Pediatric Cancer Patients.

Authors:  Rhonda J Moore; Hunter Groninger
Journal:  Cureus       Date:  2013-06-14

4.  Vocal cord paralysis during the treatment of mantle cell lymphoma with vincristine.

Authors:  Serkan Feyyaz Yalin; Sinan Trabulus; Ayse Serap Yalin; Gulsah Yenidunya Yalin; Seniz Ongoren; Mehmet Riza Altiparmak
Journal:  Int J Clin Pharm       Date:  2013-01-22

5.  Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review.

Authors:  Marie Lindhard Madsen; Hanne Due; Niels Ejskjær; Paw Jensen; Jakob Madsen; Karen Dybkær
Journal:  Cancer Chemother Pharmacol       Date:  2019-06-18       Impact factor: 3.333

6.  Successful treatment of vincristine induced ptosis and polyneuropathy with pyridoxine and pyridostigmine in a child with acute lymphoblastic leukemia.

Authors:  Kamalakshi G Bhat; Vikram Singhal; Anupama S Borker
Journal:  Indian J Med Paediatr Oncol       Date:  2012-07

7.  Vincristine-induced cranial neuropathy.

Authors:  Ahmad Talebian; Razieh Moazam Goudarzi; Mahdi Mohammadzadeh; Azadeh Sadat Mirzadeh
Journal:  Iran J Child Neurol       Date:  2014
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.